A Phase I, Single-Center, Open-Label Study Investigating the Excretion Balance, Pharmacokinetics (PK) and Metabolism of a Single Oral Dose of [14C]PCO371 and PK of an Intravenous (IV) Tracer of [14C]PCO371 in Healthy Male Subjects
Latest Information Update: 02 Nov 2021
At a glance
- Drugs PCO 371 (Primary) ; PCO 371 (Primary) ; PCO 371 (Primary)
- Indications Hypoparathyroidism
- Focus Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 25 Feb 2021 Status changed from active, no longer recruiting to completed.
- 06 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 04 Dec 2020 New trial record